Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
Ascletis has initiated a global Phase III program for oral small molecule GLP-1 ASC30, which will enroll approximately 4,600 participants with obesity or overweight, and reported positive preclinical data for its first-in-class oral GLP-1/G